Martha McGraw, MD
Neurology · Winfield, ILNPI 1437101615
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $523,885 of the $625,286 with a category attached, or 83.8%. 12 manufacturers reported payments, led by Acadia Pharmaceuticals Inc at 30.7% of the total. Among neurology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 504 payments — averaging $1240.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$192K
- Teva Pharmaceuticals USA, Inc.$175K
- MDD US Operations, LLC$111K
- Amneal Pharmaceuticals LLC$80K
- Adamas Pharmaceuticals, Inc.$32K
- Acorda Therapeutics, Inc$20K
- plus $15K from 6 others
Across 159 payments — averaging $2559.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$264K
- Amneal Pharmaceuticals LLC$69K
- H. Lundbeck A S$45K
- MDD US Operations, LLC$19K
- Sunovion Pharmaceuticals Inc.$10K
What the payments were for
- Consulting fees$36,7646%
- Speaking & faculty fees$523,88584%
- Travel & lodging$45,9647%
- Food & beverage$16,9293%
- Education$1,7450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 170 | $191,668 |
| Teva Pharmaceuticals USA, Inc. | 98 | $174,510 |
| MDD US Operations, LLC | 78 | $111,127 |
| Amneal Pharmaceuticals LLC | 75 | $80,413 |
| Adamas Pharmaceuticals, Inc. | 30 | $32,462 |
| Acorda Therapeutics, Inc | 19 | $20,206 |
| Lundbeck LLC | 15 | $14,209 |
| Boston Scientific | 2 | $252 |
| AbbVie | 9 | $211 |
| Medtronic(2 entities) | 2 | $145 |
| Sunovion Pharmaceuticals Inc. | 5 | $67 |
| Cala Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$189,057
- GOCOVRI$102,874
- Austedo XR$101,012
- AUSTEDO$72,809
- RYTARY$37,097
- CREXONT$29,136
- INBRIJA$19,868
- NORTHERA$12,244
- Xadago$1,100
- GENERAL DBS$131
- PERCEPT PC BRAINSENSE$130
How this compares
$625,286 in reported general payments places this provider in the 95th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 129 | $707,844 |
| GocovriAmantadine Hcl | 162 | $620,808 |
| RytaryCarbidopa/Levodopa | 403 | $542,530 |
| Austedo XrDeutetrabenazine | 42 | $373,253 |
| Droxidopa | 91 | $165,610 |
| AustedoDeutetrabenazine | 26 | $132,482 |
| NeuproRotigotine | 61 | $105,992 |
| XadagoSafinamide Mesylate | 40 | $100,866 |
| Rasagiline Mesylate | 167 | $42,638 |
| Rivastigmine | 129 | $32,454 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 669 | $27,657 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 418 | $15,131 |
| AmantadineAmantadine Hcl | 119 | $8,689 |
| Tetrabenazine | 29 | $4,908 |
| Ropinirole ErRopinirole Hcl | 27 | $4,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $191,668 | $707,844129 claims |
| MDD US Operations, LLCGocovri | $111,127 | $620,808162 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $80,413 | $543,447430 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $174,510 | $505,73568 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 790 neurology providers in Illinois.
Other neurology in Winfield
- Padmaja VittalWinfield$64K
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.